Combination therapies and improving overall survival in AML
GATA2 and its influence on AML
Strategies to reduce graft-versus-host disease (GvHD)
The rise of MRD in multiple myeloma: could this be an answer to a cure?
A RESPONSE to ruxolitinib: update on 4-year trial follow-up